SMA Market Snapshot: Future Spinraza Patent Loss Makes Room For Promising Myostatin Inhibitors
Executive Summary
While spinal muscular atrophy therapies Evrysdi and Zolgensma have gained ground at the expense of pioneer Spinraza, emerging myostatin inhibitors promise a complementary mechanism that could enhance functional outcomes.
You may also be interested in...
Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
Biogen’s Spinraza Stays Ahead Of Novartis And Roche Challengers In SMA – For Now
Biogen is hoping to stem the decline in its blockbuster’s revenues but Novartis’ Zolgensma and Roche’s Evrysdi look hard to stop.